A detailed history of Catalyst Financial Partners LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Catalyst Financial Partners LLC holds 329 shares of REGN stock, worth $272,688. This represents 0.07% of its overall portfolio holdings.

Number of Shares
329
Previous 326 0.92%
Holding current value
$272,688
Previous $343 Million 0.94%
% of portfolio
0.07%
Previous 0.08%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$1024.09 - $1201.76 $3,072 - $3,605
3 Added 0.92%
329 $346 Million
Q2 2024

Jul 25, 2024

BUY
$883.2 - $1071.19 $10,598 - $12,854
12 Added 3.82%
326 $343 Million
Q1 2024

Apr 22, 2024

BUY
$902.69 - $993.35 $17,151 - $18,873
19 Added 6.44%
314 $283 Million
Q4 2023

Feb 06, 2024

BUY
$775.18 - $881.7 $6,976 - $7,935
9 Added 3.15%
295 $259 Million
Q3 2023

Oct 26, 2023

BUY
$692.45 - $844.37 $198,040 - $241,489
286 New
286 $235 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $88.8B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Catalyst Financial Partners LLC Portfolio

Follow Catalyst Financial Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalyst Financial Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Catalyst Financial Partners LLC with notifications on news.